Transgene reports Q1 2020 financial position and business update

information fournie par Boursorama CP •06/05/2020 à 17:45

­- €35.3 million in cash and cash equivalents as of March 31, 2020
­- Readouts for key clinical trials remain on track
­- Minor impact from the Covid-19 pandemic seen to-date

Strasbourg, France, May 6, 2020, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter ending March 31, 2020, and provides an update on its progress of clinical trial portfolio taking into account the impact of the Covid-19 pandemic.

.../...